| 1 | the international society on | | | | | | | 5 | 0.99% |
| 2 | international society on toxinology | | | | | | | 5 | 0.99% |
| 3 | downloadable as a pdf | | | | | | | 2 | 0.40% |
| 4 | such pharmaceuticals while others | | | | | | | 1 | 0.20% |
| 5 | research continues to expand | | | | | | | 1 | 0.20% |
| 6 | ist currently held every | | | | | | | 1 | 0.20% |
| 7 | evolve and the society | | | | | | | 1 | 0.20% |
| 8 | and evolve and the | | | | | | | 1 | 0.20% |
| 9 | expand and evolve and | | | | | | | 1 | 0.20% |
| 10 | to expand and evolve | | | | | | | 1 | 0.20% |
| 11 | continues to expand and | | | | | | | 1 | 0.20% |
| 12 | currently held every two | | | | | | | 1 | 0.20% |
| 13 | toxinrelated research continues to | | | | | | | 1 | 0.20% |
| 14 | embraces these changes some | | | | | | | 1 | 0.20% |
| 15 | held every two years | | | | | | | 1 | 0.20% |
| 16 | every two years the | | | | | | | 1 | 0.20% |
| 17 | valid the scope of | | | | | | | 1 | 0.20% |
| 18 | remains valid the scope | | | | | | | 1 | 0.20% |
| 19 | purpose remains valid the | | | | | | | 1 | 0.20% |
| 20 | extensive purpose remains valid | | | | | | | 1 | 0.20% |
| 21 | this extensive purpose remains | | | | | | | 1 | 0.20% |
| 22 | the ist currently held | | | | | | | 1 | 0.20% |
| 23 | some society members are | | | | | | | 1 | 0.20% |
| 24 | these changes some society | | | | | | | 1 | 0.20% |
| 25 | extending to clinical trials | | | | | | | 1 | 0.20% |
| 26 | while others may study | | | | | | | 1 | 0.20% |
| 27 | pharmaceuticals while others may | | | | | | | 1 | 0.20% |
| 28 | is the premier scientific | | | | | | | 1 | 0.20% |
| 29 | the premier scientific and | | | | | | | 1 | 0.20% |
| 30 | premier scientific and social | | | | | | | 1 | 0.20% |
| 31 | scientific and social meeting | | | | | | | 1 | 0.20% |
| 32 | to clinical trials of | | | | | | | 1 | 0.20% |
| 33 | leads extending to clinical | | | | | | | 1 | 0.20% |
| 34 | changes some society members | | | | | | | 1 | 0.20% |
| 35 | drug leads extending to | | | | | | | 1 | 0.20% |
| 36 | toxinbased drug leads extending | | | | | | | 1 | 0.20% |
| 37 | new toxinbased drug leads | | | | | | | 1 | 0.20% |
| 38 | developing new toxinbased drug | | | | | | | 1 | 0.20% |
| 39 | and social meeting of | | | | | | | 1 | 0.20% |
| 40 | members are involved in | | | | | | | 1 | 0.20% |